Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(2.60)
# 1,964
Out of 5,012 analysts
6
Total ratings
66.67%
Success rate
14.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Assumes: Overweight | $40 | $12.40 | +222.58% | 1 | Oct 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $3.54 | +97.74% | 1 | Oct 2, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $39 → $40 | $24.92 | +60.51% | 1 | Aug 1, 2025 | |
| INVA Innoviva | Initiates: Overweight | $26 | $17.37 | +49.68% | 1 | Jul 11, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $52 | $39.51 | +31.61% | 1 | Jul 11, 2025 | |
| HROW Harrow | Initiates: Overweight | $76 | $39.74 | +91.24% | 1 | Jul 11, 2025 |
Xencor
Oct 6, 2025
Assumes: Overweight
Price Target: $40
Current: $12.40
Upside: +222.58%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $3.54
Upside: +97.74%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $39 → $40
Current: $24.92
Upside: +60.51%
Innoviva
Jul 11, 2025
Initiates: Overweight
Price Target: $26
Current: $17.37
Upside: +49.68%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $39.51
Upside: +31.61%
Harrow
Jul 11, 2025
Initiates: Overweight
Price Target: $76
Current: $39.74
Upside: +91.24%